BILLERICA, Mass.–EMD Millipore, the Life Science division of Merck KGaA of Germany, today announced that Robert Yates will become President of the EMD Millipore division as of September 1, 2011. He will report to Bernd Reckmann, Member of the Executive Board of Merck and responsible for the Chemicals business sector, which includes EMD Millipore and Performance Materials. Reckmann has led the division since Merck’s acquisition of Millipore Corporation in July 2010.

“With the successful acquisition and integration of Millipore we have established a world-class partner for the Life Sciences industry,” Reckmann said. “Now, we are entering the next phase of our growth plan focused on delivering value to our customers by driving our pioneering innovation agenda, further penetrating new and established markets and optimizing our infrastructure. To fully focus on these activities we decided to appoint a dedicated President of the EMD Millipore division and I am happy to announce today that Robert Yates will join us September 1.”

Reckmann continued: “Robert joins us from the diagnostics division of Roche, where he led the Life Science business in Penzberg, Germany and served as a member of the Diagnostics Executive Committee. He has held a range of key global executive positions at Roche during the past 22 years. He has a wealth of experience in the Life Science industry and a strong background in integrating global businesses, building performance cultures and driving strategic business value. His experience aligns with EMD Millipore’s top priorities, which include maintaining a focus on quality growth and leveraging EMD Millipore’s industry expertise to further expand the broad range of innovative solutions we provide our customers.”

Further information about Robert Yates

Robert joined Roche in Indianapolis, Indiana in 1988 as a Senior Development Engineer for Diabetes Care, and held various roles in engineering and process management before being appointed Director of Product Supply in 1996. He became Vice President of Diabetes Care Operations and Site Manager for the Indianapolis site in 2001 then moved to Basel, Switzerland in 2003 as Global Head of Business Development and Licensing.

Robert has been instrumental in setting Roche Diagnostics strategy and in leading several critical initiatives for Diagnostics throughout his career. He has spearheaded numerous strategic acquisitions. In early 2011, he was appointed head of Roche’s Life Science business, responsible for product and portfolio development, global marketing and business strategy and development.

Robert is a U.S. citizen and holds a Bachelor of Science degree in Electrical Engineering from Purdue University in Indiana.

About EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of Life Science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 68 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.